CASI Pharmaceuticals Officer Stock Option Holdings Report

This Form 3 filing reports the initial beneficial ownership of CASI Pharmaceuticals, Inc. (CASIF) securities by Hai Huang, the company's Global Chief Commercial Officer. The filing details Huang's stock option holdings totaling 270,000 ordinary shares across multiple option grants with different exercise prices and vesting schedules. Options include 75,000 fully vested options exercisable at $6.61 per share expiring January 2034, and additional tranches of 37,500 options each vesting in 2027 and 2028 at the same $6.61 exercise price. The filing also includes 30,000 options at $2.67 per share expiring June 2034, with 7,500 fully vested and additional tranches vesting in 2026, 2027, and 2028. Additionally, there are 100,000 performance-based options at $6.61 per share that become exercisable upon achievement of performance targets. All options represent the right to buy ordinary shares of the company.